RT Journal Article
T1 Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review
A1 Atallah, Edmond
A1 Freixo, Cristiana
A1 Álvarez-Álvarez, Ismael
A1 Cubero, Francisco Javier
A1 Gerbes, Alexander L
A1 Kullak-Ublick, Gerd A
A1 Aithal, Guruprasad P.
K1 Hígado -- Enfermedades
K1 Medicamentos
AB Introduction: Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes.Areas covered: This systematic review summarizes the available evidence for all biomarkers proposed to have a role in the diagnosis or prognosis of DILI. Following a comprehensive search, we included all types of studies in humans. We included DILI cases based on any threshold criteria but excluded intrinsic DILI, commonly caused by paracetamol overdose. We classified studies into diagnostic and prognostic categories and assessed their methodological quality. After reviewing the literature, 14 studies were eligible.Expert Opinion: Diagnostic studies were heterogeneous with regard to the study population and outcomes measured. Prognostic models were developed by integrating novel biomarkers, risk scores, and traditional biomarkers, which increased their prognostic ability to predict death or transplantation by 6 months. This systematic review highlights the case of need for non-genetic biomarkers that distinguish DILI from acute liver injury related to alternative etiology. Biomarkers with the potential to identify serious adverse outcomes from acute DILI should be validated in independent prospective cohorts with a substantial number of cases.
PB Taylor & Francis
YR 2021
FD 2021-11-15
LK https://hdl.handle.net/10630/23505
UL https://hdl.handle.net/10630/23505
LA eng
NO Edmond Atallah, Cristiana Freixo, Ismael Alvarez-Alvarez, F.J Cubero, Alexander L. Gerbes, Gerd A. Kullak-Ublick & Guruprasad P. Aithal (2021) Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review, Expert Opinion on Drug Metabolism & Toxicology, 17:11, 1327-1343, DOI: 10.1080/17425255.2021.1999410
NO This paper was funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283 (www.imi.europa.eu). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Translational Safety Biomarker Pipeline (TransBioLine): Enabling develop- ment and implementation of novel safety biomarkers in clinical trials and diagnosis of disease’ — ‘TransBioLine’ (‘action’). Grant Number: 821283.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026